Australia Unveils Proposals For Overhauling HTA System

Ideas proposed under the consultation include more guidance in areas such as real-world data and the assessment of genomic and tumor agnostic therapies, a single gateway for HTA filings, and more active horizon scanning.

Benefit_Cost
Australia has produced a set of options for improving HTA methods and policies • Source: Shutterstock

The Australian government has begun a consultation asking stakeholders for their views on a set of options for improving the country’s health technology assessment (HTA) policies and methods as well as funding and assessment pathways.

The options are outlined in a paper drafted by the HTA Review Reference Committee as part of the HTA...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Health Technology Assessment

Industry Criticizes Dutch Decision To Slash PARP Inhibitor Reimbursement

 

ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.

Canada Unveils Draft List of Essential Drugs For Universal Pharmacare

 

The list of essential prescription drugs and related products will shape Canada’s first national formulary for the country’s universal pharmacare program.

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla

 

Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.

More from Market Access

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By 

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

How Could MFN Pricing Impact Commercial Market?

 
• By 

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.